Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir + ACH-0143102 for 6 or 8 weeks in treatment-naive genotype 1 hepatitis C
ACTRN12614000307606Phase 2Completed
- Sponsor
- Achillion Pharmaceuticals
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sofosbuvir and odalasvir in hepatitis C virus infection, sponsored by Achillion Pharmaceuticals. Primary endpoints: Incidence of sustained virologic response after 8 weeks of active treatment and Incidence of sustained virologic response after 6 weeks of active treatment. Started Mar 2014; status: completed.
02
Drugs
sofosbuvirodalasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on ACTRN12614000307606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000307606.